Revolution Medicines, Inc. is a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers. The company focuses on RAS(ON) inhibitors designed to block active forms of RAS oncoproteins. Its pipeline includes small molecule product candidates being evaluated in clinical trials as monotherapies and in combination with chemotherapy, PD-1/VEGF bispecific antibodies, PRMT5 inhibitors, anti-EGFR agents, and PD-1 inhibitors.
Q2 FY2026 — expected 2026-09-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-25 | 2025-12-31 | 0001193125-26-071563 | EDGAR | 97K words |
| 2025-02-26 | 2024-12-31 | 0000950170-25-027736 | EDGAR | 100K words |
| 2024-02-26 | 2023-12-31 | 0000950170-24-020145 | EDGAR | 98K words |
| 2023-02-27 | 2022-12-31 | 0000950170-23-004645 | EDGAR | 93K words |
| 2022-02-28 | 2021-12-31 | 0000950170-22-002297 | EDGAR | 93K words |
| 2021-03-02 | 2020-12-31 | 0001564590-21-010276 | EDGAR | 103K words |
| 2020-03-30 | 2019-12-31 | 0001564590-20-014169 | EDGAR | 122K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-05 | 2026-06-30 | 0001193125-26-335104 | EDGAR | 73K words |
| 2025-11-05 | 2025-09-30 | 0001193125-25-266923 | EDGAR | 69K words |
| 2025-08-06 | 2025-06-30 | 0000950170-25-104022 | EDGAR | 67K words |
| 2025-05-07 | 2025-03-31 | 0000950170-25-065660 | EDGAR | 62K words |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122303 | EDGAR | 68K words |
| 2024-08-07 | 2024-06-30 | 0000950170-24-092783 | EDGAR | 67K words |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055655 | EDGAR | 63K words |
| 2023-11-06 | 2023-09-30 | 0000950170-23-059391 | EDGAR | 63K words |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039805 | EDGAR | 64K words |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018805 | EDGAR | 62K words |
| 2022-11-07 | 2022-09-30 | 0000950170-22-022590 | EDGAR | 65K words |
| 2022-08-09 | 2022-06-30 | 0000950170-22-016059 | EDGAR | 64K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-01 | 0001193125-26-377362 | EDGAR | 1K words |
| 2026-08-26 | 0001193125-26-366931 | EDGAR | 1K words |
| 2026-08-05 | 0001193125-26-335039 | EDGAR | 3K words |
| 2026-02-25 | 0001193125-26-071517 | EDGAR | 3K words |
| 2025-11-05 | 0001193125-25-266836 | EDGAR | 2K words |
| 2025-10-17 | 0001193125-25-241736 | EDGAR | 1K words |
| 2025-09-10 | 0001193125-25-200078 | EDGAR | 3K words |
| 2025-08-06 | 0000950170-25-103983 | EDGAR | 2K words |
| 2025-06-27 | 0001193125-25-151254 | EDGAR | 1K words |
| 2025-06-24 | 0001193125-25-145242 | EDGAR | 2K words |
112 total filings indexed. 83 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001628171 |
| Ticker | RVMD |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.revmed.com |
| Listed | 2020-02-13 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/RVMD (~200 tokens, structured JSON with cryptographic provenance)